bioRxiv Science⌕ Search

Biology subjects

Orlicky, S.

Publications and source records attributed to Orlicky, S..

2 recordsLinked to original sources

Engineered Antigen-Binding Fragments for Enhanced Crystallisation of Antibody:Antigen Complexes

The atomic-resolution structural information that X-ray crystallography can provide on the binding interface between a Fab and its cognate antigen is highly valuable for understanding the mechanism of interaction. However, many Fab:antigen complexes are recalcitrant to crystallisation, making the endeavour a significant effort with no guarantee of success. Consequently, there have been significant steps taken to increase the likelihood of Fab:antigen complex crystallisation by altering the Fab framework. In this investigation, we applied the surface entropy reduction strategy coupled with phage-display technology to identify a set of surface substitutions that improve the propensity of a human Fab framework to crystallise. In addition, we showed that combining these surface substitutions with previously reported Crystal Kappa and elbow substitutions results in a striking improvement in Fab and Fab:antigen complex crystallisability, revealing a synergistic relationship between these sets of substitutions. Through comprehensive Fab and Fab:antigen complex crystallisation screenings followed by structure determination and analysis, we defined the roles that each of these substitutions play in facilitating crystallisation and how they complement each other in the process.

biochemistry↗

SCF-FBXW7 regulates G2-M progression through control of CCNL1 ubiquitination

FBXW7, which encodes a substrate specific receptor of an SCF E3 ligase complex, is a frequently mutated human tumor suppressor gene known to regulate the post-translational stability of various proteins involved in cellular proliferation. Here, using genome-wide CRISPR screens we report a novel synthetic lethal genetic interaction between FBXW7 and CCNL1 and describe CCNL1 as a new substrate of the SCF-FBXW7 E3 ligase. Further analysis showed that the CCNL1-CDK11 complex is critical at the G2-M phase of the cell cycle since defective CCNL1 accumulation, resulting from FBXW7 mutation, leads to shorter mitotic time. Cells harboring FBXW7 loss-of-function mutations are hypersensitive to treatment with a CDK11 inhibitor, highlighting a genetic vulnerability that could be leveraged for cancer treatment.

cancer biology↗